Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1998 May;36(5):1220–1225. doi: 10.1128/jcm.36.5.1220-1225.1998

Detection of Kanamycin-Resistant Mycobacterium tuberculosis by Identifying Mutations in the 16S rRNA Gene

Yasuhiko Suzuki 1,*, Chihiro Katsukawa 2, Aki Tamaru 2, Chiyoji Abe 3, Masanao Makino 4, Yasuo Mizuguchi 5, Hatsumi Taniguchi 6
PMCID: PMC104803  PMID: 9574680

Abstract

In Mycobacterium smegmatis and a limited number of Mycobacterium tuberculosis strains, the involvement of alterations of the 16S rRNA gene (rrs) in resistance to kanamycin has been shown. To investigate the extent to which mutations in a specific region of the rrs gene and the kanamycin-resistant phenotype in clinically isolated M. tuberculosis strains were correlated, 43 kanamycin-resistant strains (MICs, ≧200 μg/ml), 71 kanamycin-susceptible strains, and 4 type strains were examined. The 300-bp DNA fragments carrying the rrs gene and the intervening sequence between the rrs gene and 23S rRNA (rrl) gene fragments were amplified by PCR and were subjected to PCR-based direct sequencing. By comparing the nucleotide sequences, substitutions were found in 29 of 43 (67.4%) kanamycin-resistant clinical isolates at positions 1400, 1401, and 1483 but in none of the 71 sensitive isolates or the 4 type strains. The most frequent substitution, from A to G, occurred at position 1400. A substitution from C to T at position 1401 was found once. Two clinical isolates carried the double mutation from C to A at position 1401 and from G to T at position 1483. In addition, we found that these mutants can be distinguished from wild-type strains by digestion with the restriction endonucleases TaiI and Tsp45I. Furthermore, we found that the genotypes of kanamycin-resistant strains can be discriminated from each other by digestion with a restriction endonuclease, BstUI or DdeI.


Control of tuberculosis caused by drug-resistant Mycobacterium tuberculosis has become one of the major problems throughout the world (1, 8). However, the detection of drug-resistant phenotypes of M. tuberculosis takes at least 3 and 6 weeks by the direct and indirect methods, respectively. Thus, treatment is prescribed empirically. Patients who fail to respond to drugs remain infectious (19). They may be a source of transmission of infections from patient to patient, from patients to people who are giving medical treatment (10), and from a patient to a member(s) of his or her family (17). Thus, the establishment of a rapid, simple, and reliable method for the detection of drug-resistant phenotypes of M. tuberculosis is one of the most urgent needs in the treatment of tuberculosis patients.

Understanding of the molecular basis of resistance might help in the establishment of a novel method for the detection of drug-resistant M. tuberculosis strains. This approach has been pursued, and the detection of drug-resistant M. tuberculosis by genetic methods has become possible. Nearly 95% of rifampin-resistant strains can be detected by analyzing a certain part of the RNA polymerase β-subunit gene (21, 25, 27, 29). About 80% of streptomycin-resistant strains carry mutations on either the rpsL or the rrs gene (12, 15, 21). It has also been known that resistance to isoniazid is due to mutations in the catalase-peroxidase gene (katG) (2, 31), the inhA gene (4), or the aphC (30) gene. The gene responsible for resistance to ethambutol has been reported to encode arabinosyltransferases in M. avium (6). The pncA gene encoding pyrazinamidase-nicotinamidase turned out to be a gene responsible for pyrazinamide resistance (23). Caceres et al. (7) reported that the overexpression of the d-alanine racemase gene confers resistance to d-cycloserine in Mycobacterium smegmatis. In addition, quinolone-resistant mutations were found on the gyrA gene, as has been seen in other bacteria (26). However, a method for the detection of kanamycin-resistant strains has not yet been established.

Kanamycin is one of the key second-line drugs for the treatment of tuberculosis. Patients who are suffering from tuberculosis caused by multidrug-resistant strains with resistance to the first-line antituberculosis drugs such as rifampin, isoniazid, ethambutol, streptomycin, or pyrazinamide have a poor prognosis (15). For such patients, kanamycin is one of the best choices for treatment.

In bacteria, resistance to kanamycin is attributed to three mechanisms. One mechanism involves an aminoglycoside-modifying enzyme carried by transposons (22). The second mechanism is specific methylation of rRNA. Modification of the rRNA at position 1405 or 1408 was responsible for kanamycin resistance (5). The third mechanism involves nucleotide changes in the 3′ part of the 16S rRNA gene (rrs) (3, 9). The structural and functional organization of rRNA is highly conserved among bacteria, so it is reasonable to consider that the same mutation results in resistance to kanamycin in mycobacteria, as was seen in other bacteria. Recently, we have used a genetic conjugation system to show that the nucleotide substitution from A to G at position 1389 of the 16S rRNA gene in M. smegmatis was responsible for the kanamycin-resistant phenotype. In the same study we showed with a limited number of strains that there exist some correlations between the mutation from A to G at position 1400 of the 16S rRNA gene, equivalent to position 1389 of M. smegmatis, and a kanamycin-resistant phenotype in M. tuberculosis (28).

To make sure that this observation would be generally applicable for the identification of clinically isolated M. tuberculosis strains with the kanamycin-resistant phenotype, we have amplified and sequenced the identical fragment reported previously (28) and compared the results.

In this paper, we discuss the use of sequencing of the rrs gene segment and PCR product-restriction fragment length polymorphism (PCR-RFLP) analysis as tools for the identification of kanamycin-resistant M. tuberculosis strains.

MATERIALS AND METHODS

Bacterial strains.

Kanamycin-susceptible and -resistant clinical isolates of M. tuberculosis were kindly provided by the following institutions: Hiroshima University (Hiroshima, Japan), Osaka Prefectural Habikino Hospital (Osaka, Japan), Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (Tokyo, Japan), National Minami-Fukuoka Hospital (Fukuoka, Japan), National Fukuoka-higashi Hospital (Fukuoka, Japan), National Sanyoso Hospital (Yamaguchi, Japan), National Ohmuta Hospital (Fukuoka, Japan), National Cyubu Hospital (Aichi, Japan), Aihoku Hospital (Aichi, Japan), and National Sapporo-minami Hospital (Hokkaido, Japan). The type strains M. tuberculosis H37Rv, H37Ra, Aoyama B, and ATCC 35416 have been maintained on Ogawa egg medium (Nissui Seiyaku Co., Ltd., Tokyo, Japan) in our laboratory. Drug susceptibility testing was performed by the conventional method with Ogawa egg medium. Resistance was generally defined as survival of the bacilli at the following drug concentrations: kanamycin, 100 μg/ml; streptomycin, 20 μg/ml; rifampin, 50 μg/ml; isoniazid, 1 μg/ml; and ethambutol, 5 μg/ml. The susceptibilities of the strains are as indicated in Table 1.

TABLE 1.

Resistance of the clinical isolates used in this study to first-line antituberculosis drugs

Drug(s)a No. of strains with the following kanamycin susceptibility resistant to the drug(s):
Susceptible Resistant
None 2 0
R 4 0
I 0 0
S 6 1
E 0 0
R, I 3 2
R, S 2 2
R, E 0 0
I, S 1 2
I, E 8 0
S, E 2 1
R, I, S 8 2
R, I, E 7 7
R, S, E 8 5
I, S, E 6 2
R, I, S, E 14 19
a

Abbreviations: R, rifampin; I, isoniazid; S, streptomycin; E, ethambutol. 

DNA preparation.

DNAs for PCR were prepared by mechanical disruption as described previously (25). Briefly, a single colony on Ogawa medium was picked and suspended in 0.5 ml of lysis buffer consisting of 0.3 M Tris-HCl (pH 8.0), 0.1 M NaCl, and 6 mM EDTA in a conical, 2-ml, screw-cap vial, one-fourth of which was filled with 0.17-mm, acid-washed sterile glass beads. Mycobacterial cells were disrupted by vigorous shaking with 0.5 ml of chloroform on a Mini-BeadBeater cell disrupter (Biospec Products, Bartlesville, Okla.) for 5 min. After centrifugation the DNAs in the upper layer were further purified by phenol-chloroform extraction, concentrated by ethanol precipitation, and dissolved in 300 μl of TE buffer consisting of 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA.

PCR procedure.

A pair of primers, TBrrs1250 and TBrrivs38, was used to amplify a part of the 16S rRNA gene of M. tuberculosis (Fig. 1). Ten nanograms of DNA was used in a 50-μl PCR mixture consisting of 50 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, a 0.2 mM concentration of each deoxynucleoside triphosphate, a 1 mM concentration of each primer (TBrrs1250 and TBrrivs38), and 2.5 U of ExTaq DNA polymerase (Takara Shuzo Co. Ltd., Kyoto, Japan). PCR was performed as follows: 94°C for 10 min, 35 cycles of 30 s at 94°C, 30 s at 55°C, and 60 s at 72°C, followed by 5 min at 72°C for completion. A PCR thermal cycler (MP; Takara Shuzo) was used throughout.

FIG. 1.

FIG. 1

Strategy and primers used for the PCR amplification and direct sequencing of the 3′ part of the 16S rRNA gene of M. tuberculosis. Two primers, named TBrrs1250 and TBrrivs38, for amplification of the DNA fragments in which we were interested, were designed on the basis of the sequence of the rrs gene and spacer region reported by us (24) and Kempsell et al. (16). DNA fragments were amplified by using primers TBrrs1250 and TBrrivs38, and their sequences were determined by using TBrrs1285F and TBrrivs15F separately.

PCR-based sequencing of PCR products.

PCR products were subjected to the purification step by agarose gel electrophoresis. The block containing the bands in which we were interested was sliced out of the agarose gel and frozen at −80°C for 10 min, followed by centrifugation at 15,000 × g for 5 min. The concentration of DNA fragments in the effluent obtained after the centrifugation was determined by comparing the density of the band with those of the HindIII-digested bacteriophage λ DNA fragments (Takara Shuzo) of known concentration. DNA sequences were obtained by a modified dideoxy procedure by using 0.5 to 1 μg of template per sequencing reaction with an Autocycle DNA sequencing kit (Pharmacia Biotech Japan Inc., Tokyo, Japan) or a Sequencing PRO Autosequencer Core Kit for Labeled Primer (TOYOBO Inc., Osaka, Japan) according to the manufacturer’s procedure. The primers used for the sequencing were TBrrs1285F and TBrrivs15F (Fig. 1). The reaction mixtures were analyzed with an A.L.F. fluorescent auto DNA sequencer (Pharmacia Biotech). Every PCR product from both strands was sequenced.

PCR-RFLP analysis.

The PCR products obtained by using primers TBrrs1250 and TBrrivs38 were precipitated with 0.1 volume of 3 M sodium acetate and 2 volumes of ethanol, dissolved in TE buffer, and then digested with the restriction endonucleases TaiI, Tsp45I, BstUI, and DdeI (New England Biolabs, Inc., Beverly, Mass.) according to the manufacturer’s procedure. Digested PCR products were separated by electrophoresis on a 4% agarose gel (NuSieve GTG agarose; FMC Bioproducts Inc., Rockland, Maine). The resulting bands were then visualized by staining with SYBR green nucleic acid gel stain (FMC Bioproducts).

RESULTS

Nucleotide sequence analysis of 3′ part of 16S rRNA gene from kanamycin-resistant and -susceptible M. tuberculosis.

DNAs were extracted from a panel of kanamycin-resistant and -susceptible clinical isolates and type strains of M. tuberculosis. DNA fragments of 300 bp containing the 3′ one-fifth of the 16S rRNA gene and 38 bp of the intervening sequence between the 16S and the 23S rRNA genes were made by PCR and were used for PCR-based direct sequencing. When the chromosomal DNAs of these M. tuberculosis strains were analyzed by PCR by using the strategy described in Materials and Methods, the expected products with a length of 300 bp were obtained in all cases. To reduce artifacts resulting from the misincorporation of nucleotides by the Taq DNA polymerase and cloning errors, PCR-based direct sequencing was used. The PCR-amplified DNA fragments were separated by electrophoresis on 1% agarose gels and were cut out of the gels as blocks. Template DNA solutions were obtained in the supernatant after freezing the gel block and centrifuging it at 20,000 × g for 5 min. The nucleotide sequences of the regions in which we were interested were obtained by the dideoxy method by using PCR-amplified DNAs as templates. When comparing the nucleotide sequences with those for the same region reported by us (24) and Kempsell et al. (16), all 71 clinically isolated kanamycin-susceptible M. tuberculosis strains and the 4 type strains (strains H37Rv, H37Ra, Aoyama B, and ATCC 35416) exhibited identical nucleotide sequences. In striking contrast, three different mutations were found among the 29 kanamycin-resistant M. tuberculosis strains. An A-to-G nucleotide substitution at position 1400, the most frequent mutation, was observed in 26 of the 43 (60.5%) kanamycin-resistant clinical isolates. The mutant genotype with a substitution from C to T at position 1401 was found only once (2.3%). As described above, most of the substitutions were single nucleotide substitutions. Double nucleotide substitutions (from C to A at position 1401 and from G to T at position 1483) were found in two isolates (4.7%). However, no mutations were identified in the specific region of the rrs genes of 14 kanamycin-resistant isolates (32.6%) examined in this study (Table 2).

TABLE 2.

Genotypes of rrs genes of kanamycin-resistant and -susceptible clinical isolates of M. tuberculosis

Kanamycin susceptibility No. of strains tested No. of strains with a mutation(s) at the following position(s):
None 1400 (A → G) 1401 (C → T) 1401 (C → A) + 1483 (G → T)
Susceptible 71 71 0 0 0
Resistant 43 14 26 1 2

Detection of kanamycin-resistant strains by PCR-RFLP analysis.

The PCR products generated with primers TBrrs1250 and TBrrivs38 were subjected to digestion with restriction endonuclease TspI, TaiI, BstUI, or DdeI. As indicated in Fig. 2A, the PCR products from kanamycin-susceptible strains carried the Tsp45I recognition sequences (^GTCAC [where the caret represents the cutting position]; from positions 1397 to 1401) and the TaiI recognition sequence (ACGT^; from positions 1400 to 1403) at the site at which most of the mutations were found. The dominant genotype of kanamycin-resistant clinical isolates contained the novel restriction site of BstUI (CG^CG; from positions 1399 to 1402) as a result of conversion of the nucleotide at position 1400 from an A to a G. The genotype containing a double substitution, from C to A at position 1401 and from G to T at position 1483, thereby acquired the restriction recognition sequence of DdeI (C^TAAG; from positions 1482 to 1486), as shown in Fig. 2B. Thus, the PCR products obtained from wild-type sequences could be digested with both Tsp45I and TaiI (Fig. 3A and B, respectively). On the contrary, BstUI and DdeI digested the PCR product with the A-to-G mutation at position 1400 and the G-to-T mutation at position 1483 (Fig. 3C and D, respectively). The lengths of the DNA fragments obtained by digesting the amplicon with these restriction enzymes exhibited good agreement with the lengths suggested by the nucleotide sequence when the fragments were analyzed by agarose gel electrophoresis containing the SYBR green nucleic acid gel stain (Fig. 3).

FIG. 2.

FIG. 2

Expected restriction digestion patterns of amplicons. The restriction digestion patterns of the DNA fragments in which we were interested, which were amplified by using primers TBrrs1250 and TBrrivs38 as described in the legend to Fig. 1, are presented schematically. (A) Alignment of nucleotide sequences of wild-type (wt) and mutant alleles from positions 1381 to 1420. The restriction endonuclease digestion sites of Tsp45I, TaiI, and BstUI are indicated below the sequences. (B) Alignment of nucleotide sequences of wild-type and mutant alleles from positions 1464 to 1503. The restriction endonuclease digestion site of DdeI is indicated below the sequences. (C) PCR-generated fragments of the wild-type sequence are digested by Tsp45I, whereas the fragments of strains with mutant alleles are not. (D) PCR-generated fragments of the wild-type sequence are digested by TaiI into three fragments, whereas the fragments of strains with mutant alleles are digested into two fragments. (E) PCR-generated fragments of the wild-type sequence and mutated sequence at position 1401 are resistant to digestion with BstUI, whereas the fragments of strains with mutant alleles at position 1400 (from A to G) are digested into two fragments. (F) PCR-generated fragments of strains with the mutation at position 1483 (from G to T) are digested into four fragments, whereas the fragments of other strains are digested into three fragments.

FIG. 3.

FIG. 3

Analysis of the PCR products by PCR-RFLP analysis. The DNA fragments in which we were interested were amplified by using primers TBrrs1250 and TBrrivs38, as described in the legend to Fig. 1, digested with restriction endonucleases, and analyzed by electrophoresis on a 4% agarose gel. (A) PCR-generated fragments were digested with Tsp45I. (B) PCR-generated fragments were digested with TaiI. (C) PCR-generated fragments were digested with BstUI. (D) PCR-generated fragments were digested with DdeI. Lane M, DNA marker; lane 1, PCR product from a kanamycin-susceptible isolate; lane 2, PCR product from a kanamycin-resistant isolate with the wild-type sequence; lane 3, PCR product from a kanamycin-resistant isolate with a mutation at position 1401 (C to T); lane 4, PCR product from a kanamycin-resistant isolate with a mutation at position 1400 (A to G); lane 5, PCR product from a kanamycin-resistant isolate with mutations at position 1401 (C to A) and position 1483 (G to T). Numbers on the left indicate the lengths (in base pairs) of the DNA marker (pUC118 HinfI digests).

DISCUSSION

In an earlier study, we showed that kanamycin resistance in M. smegmatis is due to some alterations in a 30S ribosome subunit (31). Recently, the precise positions of the mutations in M. smegmatis were identified by use of the conjugation system (28) (Fig. 4). The base substitution at position 1389 (from A to G), which is equivalent to position 1400 of M. tuberculosis, was found in the high-level kanamycin-resistant mutants. Kanamycin-resistant M. smegmatis had other mutations, from T to A at position 1387 (equivalent to position 1398 of M. tuberculosis) and from G to T at position 1473 (equivalent to position 1483 of M. tuberculosis). The mutation at position 1473 in M. smegmatis was characterized as the key mutation for viomycin and capreomycin resistance as well as kanamycin resistance (28). In Escherichia coli, mutations at positions 1408, 1409, and 1491 (equivalent to positions 1400, 1401, and 1483 of M. tuberculosis, respectively) caused resistance to kanamycin, paromomycin, and other aminoglycoside antibiotics (9, 20).

FIG. 4.

FIG. 4

Locations of mutations in the rrs genes that cause aminoglycoside resistance in three bacterial species. A portion including the bases that were reported to be responsible for aminoglycoside resistance are reproduced from the secondary structure proposed by Moazed and Noller (20). Arrows indicate the bases responsible for resistance in E. coli (9), M. tuberculosis (this study), and M. smegmatis (28).

In this study of M. tuberculosis, mutated bases were observed in the DNAs of 29 strains of kanamycin-resistant clinical isolates. Twenty-six of 29 strains carried the base substitution from A to G at position 1400 (equivalent to position 1389 of M. smegmatis and position 1408 of E. coli), which appeared to be responsible for kanamycin resistance. In addition to this mutation, two clinical isolates possessed the mutation from C to A at position 1401 (equivalent to position 1390 of M. smegmatis and position 1409 of E. coli), as well as the mutation from G to T at position 1483 (equivalent to positions 1473 and 1491 of M. smegmatis and E. coli, respectively). The mutation at position 1473 in M. smegmatis was characterized as the key mutation for viomycin, capreomycin, and kanamycin resistance. In E. coli, an equivalent mutation appeared to be responsible for resistance to aminoglycoside antibiotics. So, the mutation at position 1401, together with the mutation at position 1483 in M. tuberculosis found in this study, may be responsible for kanamycin resistance. Interestingly, nucleotide 1401 is thought to hydrogen bond with nucleotide 1483. So, the conversion from a C to an A at position 1401 and a G to a T at position 1484 weakens the strength of hydrogen bonding (Fig. 3). The same kind of nucleotide substitution which weakens the strength of hydrogen bonding was found at position 1401 (from C to T). This mutation was not seen in kanamycin-resistant M. smegmatis but was seen in E. coli. By analogy, it appears possible that this mutation may be responsible for the kanamycin resistance in the M. tuberculosis strains that we studied.

In the kanamycin-resistant M. tuberculosis strains analyzed in this study, mutations in the rrs gene fragment were found in 67.4% (29 of 43) of the strains. This percentage is lower than that for mutations in the specific region of the rpoB gene (more than 95%) in rifampin-resistant M. tuberculosis (21, 25, 27, 29). Similar observations were made for both streptomycin- and isoniazid-resistant M. tuberculosis strains. Drug resistance cannot be explained by mutations in one gene region in these cases. At least three enzymes are involved in resistance to isoniazid in M. tuberculosis (2, 4, 30, 32), and at least two genes are responsible for streptomycin resistance (12, 15, 21). So, causes of resistance other than the mutations in the region studied in this experiment should be considered. One candidate gene that may be involved in kanamycin resistance is elongation factor G. Aminoglycoside antibiotics have been reported to bind to the A site of the 30S ribosome and inhibit translocation (11, 18). Elongation factor G is known to be involved in translocation. Fusidic acid-resistant mutants of Salmonella typhimurium with mutations in elongation factor G exhibited the kanamycin-resistant phenotype (14). Considering all of these facts, searching for mutations in the elongation factor G gene of kanamycin-resistant M. tuberculosis strains may lead to another cause of kanamycin resistance. The existence of genetic elements carrying aminoglycoside-modifying enzymes such as Tn5 in E. coli (22) have not yet been disproven. Moreover, there may exist specific methylases that can modify the rRNA at position 1405 or 1408, as described for Streptomyces lividans (5). In addition, permeability barriers (13) are also candidates for the cause of kanamycin resistance in M. tuberculosis.

Finally, we have tried to develop a rapid and simple method for the detection of kanamycin-resistant M. tuberculosis by applying PCR-RFLP techniques. The wild-type sequence of the rrs gene turned out to contain two restriction sites near the position where mutations associated with kanamycin resistance were found. It was suggested from the sequence of the amplicon that all PCR-generated DNA fragments with mutations at either position 1400 or position 1401 were resistant to Tsp45I, whereas PCR-generated DNA fragments of the wild-type sequence were digested into two fragments of 175 and 125 bp (Fig. 2A and C). TaiI was supposed to digest the wild-type amplicon into three fragments with lengths of 171, 98, and 31 bp, whereas the PCR product carrying the mutant sequence will be cut into only two fragments of 202 and 98 bp (Fig. 2A and D). The mutant allele with the base conversion from A to G at position 1400 has the BstUI restriction sequence (CG^CG; spanning from positions 1400 to 1403) (Fig. 2A). The PCR-generated DNA fragment with this mutant sequence was guessed to be digested into two fragments with lengths of 178 and 122 bp, respectively, whereas the PCR-generated DNA fragment with the wild-type sequence or some other mutant sequence was guessed to be resistant to this enzyme (Fig. 2E). In addition, the mutation at position 1483 (from G to T) converts the PCR product into one that is digestible by the restriction endonuclease DdeI (recognition sequence, C^TRAG) (Fig. 2B) into four fragments with lengths of 196, 48, 38, and 14 bp (Fig. 2F). The lengths of the DNA fragments obtained by restriction digestion exhibited good agreement, with one exception, with the lengths suggested by the nucleotide sequence of amplicon when analyzed by agarose gel electrophoresis (Fig. 3); the exception was a 14-bp DdeI fragment which was too short to be detected with the agarose gel used in this study. All of the mutant genotypes found in this study can be identified by digesting the PCR products with at least three restriction endonucleases. However, the displacement of restriction fragments in TaiI and DdeI digestion are very small, and much care should be taken in running the assays and interpreting the results.

It is not clear that the results obtained in this study with clinically isolated strains only from Japan are applicable to strains from other countries. For strains resistant to other drugs, such as rifampin and streptomycin, however, the genes with mutations responsible for resistance in Japanese isolates were the same as the genes with mutations responsible for resistance in isolates from other countries (15, 25, 27). From this finding, the results obtained in this study may be applicable to strains from all over the world. In addition, further studies are necessary to answer the question of whether the results obtained in this study are applicable to nontuberculous mycobacterial strains.

ACKNOWLEDGMENTS

We thank N. Hirota, N. Miyazaki, H. Fukunaga, K. Ishibashi, S. Yamori, S. Kawahara, S. Sumi, and all members of the Department of Clinical Laboratory in Habikino Hospital for gifts of clinical mycobacterial isolates.

REFERENCES

  • 1.Al-Drainev I. Drug resistance in tuberculosis. J Chemother. 1990;2:147–151. doi: 10.1080/1120009x.1990.11739007. [DOI] [PubMed] [Google Scholar]
  • 2.Altamirano M, Marostenmaki J, Wong A, FitzGerald M, Black W A, Smith J A. Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis. 1994;169:1162–1165. doi: 10.1093/infdis/169.5.1162. [DOI] [PubMed] [Google Scholar]
  • 3.Apirion D, Schlessinger D. Coresistance to neomycin and kanamycin by mutations in an Escherichia coli locus that affects ribosomes. J Bacteriol. 1968;96:768–776. doi: 10.1128/jb.96.3.768-776.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Sun Um K, Wilson T, Collins D, de Lisle G, Jacobs W R., Jr inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263:227–230. doi: 10.1126/science.8284673. [DOI] [PubMed] [Google Scholar]
  • 5.Beauclerk A A D, Cundliffe E. Site of action of two ribosomal RNA methylases responsible for resistance to aminoglycoside. J Mol Biol. 1987;193:661–671. doi: 10.1016/0022-2836(87)90349-4. [DOI] [PubMed] [Google Scholar]
  • 6.Belanger A E, Besra G S, Ford M E, Mikusova K, Belisle J T, Brennan P J, Inamine J M. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA. 1996;15:11919–11924. doi: 10.1073/pnas.93.21.11919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Caceres N E, Harris N B, Wellehan J F, Feng Z, Kapur V, Barlette R G. Overexpression of the d-alanine racemase gene confers resistance to d-cycloserine in Mycobacterium smegmatis. J Bacteriol. 1997;179:5046–5055. doi: 10.1128/jb.179.16.5046-5055.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Culliton B. Drug-resistant TB may bring epidemic. Nature. 1992;356:473. doi: 10.1038/356473a0. [DOI] [PubMed] [Google Scholar]
  • 9.De Stasio E A, Moazed D, Noller H F, Dahlberg A E. Mutations in 16S ribosomal RNA disrupt antibiotic-RNA interactions. EMBO J. 1989;8:1213–1216. doi: 10.1002/j.1460-2075.1989.tb03494.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dunlap N E, Kimerling M E. Drug-resistant tuberculosis in adults: implications for the health care worker. Infect Agents Dis. 1994;3:245–255. [PubMed] [Google Scholar]
  • 11.Fourmy D, Recht M I, Blanchard S C, Puglisi J D. Structure of the A site of Escherichia coli 16S ribosomal RNA. Science. 1996;274:1367–1371. doi: 10.1126/science.274.5291.1367. [DOI] [PubMed] [Google Scholar]
  • 12.Honore N, Cole S T. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother. 1994;38:238–242. doi: 10.1128/aac.38.2.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hui J, Gordon N, Kajkioka R. Permeability barrier to rifampin in mycobacteria. Antimicrob Agents Chemother. 1977;11:773–779. doi: 10.1128/aac.11.5.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Johanson U, Hughes D. Fusidic acid-resistant mutants define three regions in elongation factor G of Salmonella typhimurium. Gene. 1994;143:55–59. doi: 10.1016/0378-1119(94)90604-1. [DOI] [PubMed] [Google Scholar]
  • 15.Katsukawa C, Tamaru A, Miyata Y, Abe C, Makino M, Suzuki Y. Characterization of the rpsL and rrs genes of streptomycin-resistant clinical isolates of Mycobacterium tuberculosis in Japan. J Appl Microbiol. 1997;83:634–640. doi: 10.1046/j.1365-2672.1997.00279.x. [DOI] [PubMed] [Google Scholar]
  • 16.Kempsell K E, Ji Y E, Estrada I C E, Colston M J, Cox R A. The nucleotide sequence of the promoter, 16S rRNA and spacer region of the ribosomal RNA operon of Mycobacterium tuberculosis and comparison with Mycobacterium leprae precursor rRNA. J Gen Microbiol. 1992;138:1717–1727. doi: 10.1099/00221287-138-8-1717. [DOI] [PubMed] [Google Scholar]
  • 17.Kritski A L, Marques M J O, Rabahi M F, Vieira M A M S, Werneck-Barroso E, Carvalho C E S, Angrade G D N, Bravo-De-Souza R, Andrade L M, Gontijo P P, Riley L W. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996;153:331–335. doi: 10.1164/ajrccm.153.1.8542139. [DOI] [PubMed] [Google Scholar]
  • 18.Misumi M, Tanaka N. Mechanism of inhibition of translocation by kanamycin and viomycin: a comparative study with fusidic acid. Biochem Biophys Res Commun. 1980;92:647–654. doi: 10.1016/0006-291x(80)90382-4. [DOI] [PubMed] [Google Scholar]
  • 19.Mitchison D, Nunn A. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986;133:423–430. doi: 10.1164/arrd.1986.133.3.423. [DOI] [PubMed] [Google Scholar]
  • 20.Moazed D, Noller H F. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature. 1987;327:389–394. doi: 10.1038/327389a0. [DOI] [PubMed] [Google Scholar]
  • 21.Morris S, Bai G H, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis. 1995;171:954–960. doi: 10.1093/infdis/171.4.954. [DOI] [PubMed] [Google Scholar]
  • 22.Rothstein S J, Jorgensen R A, Yin J C, Yongdi Z, Johnson R C, Reznikoff W S. Genetic organization of Tn5. Cold Spring Harbor Symp Quant Biol. 1981;451:99–105. doi: 10.1101/sqb.1981.045.01.018. [DOI] [PubMed] [Google Scholar]
  • 23.Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Med. 1996;2:662–667. doi: 10.1038/nm0696-662. [DOI] [PubMed] [Google Scholar]
  • 24.Suzuki Y, Nagata A, Ono Y, Yamada T. Complete nucleotide sequence of the 16S rRNA gene of Mycobacterium bovis BCG. J Bacteriol. 1988;170:2886–2889. doi: 10.1128/jb.170.6.2886-2889.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Suzuki Y, Katsukawa C, Inoue K, Yin Y P, Tasaka H, Ueba N, Makino M. Mutations in rpoB gene of rifampicin resistant clinical isolates of Mycobacterium tuberculosis in Japan. J Jpn Assoc Infect Dis. 1995;69:413–419. doi: 10.11150/kansenshogakuzasshi1970.69.413. [DOI] [PubMed] [Google Scholar]
  • 26.Takiff H E, Salazar L, Guerrero C, Philipp W, Huang W M, Kreiswirth B, Cole S T, Jacobs W R, Jr, Telenti A. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone-resistant mutations. Antimicrob Agents Chemother. 1994;38:773–780. doi: 10.1128/aac.38.4.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Taniguchi H, Aramaki H, Nikaido Y, Mizuguchi Y, Nakamura M, Koga T, Yoshida S. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett. 1996;144:103–108. doi: 10.1111/j.1574-6968.1996.tb08515.x. [DOI] [PubMed] [Google Scholar]
  • 28.Taniguchi H, Chang B, Abe C, Nikaido Y, Mizuguchi Y, Yoshida S. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J Bacteriol. 1997;179:4795–4801. doi: 10.1128/jb.179.15.4795-4801.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S T, Colston M J, Matter L, Schopfer K, Bodmer T. Detection of rifampicin-resistance mutants in Mycobacterium tuberculosis. Lancet. 1993;341:647–650. doi: 10.1016/0140-6736(93)90417-f. [DOI] [PubMed] [Google Scholar]
  • 30.Wilson T M, Collins D M. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol. 1996;19:1025–1034. doi: 10.1046/j.1365-2958.1996.449980.x. [DOI] [PubMed] [Google Scholar]
  • 31.Yamada T, Masuda K, Mizuguchi Y, Suga K. Altered ribosomes in antibiotic-resistant mutants of Mycobacterium smegmatis. Antimicrob Agents Chemother. 1976;9:817–823. doi: 10.1128/aac.9.5.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Zhang Y, Heym B, Allen B, Young D, Cole S T. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358:591–593. doi: 10.1038/358591a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES